Abstract:Biomarkers for emphysema and specifi cally for alpha-1 antitrypsin defi ciency (AATD)-related emphysema have been investigated vigorously because biomarkers off er the promise of important benefi ts such as assessing disease status, monitoring disease progression, assessing the eff ects of therapy, and providing important outcome measures for research. Because of these promising benefi ts, the appetite to identify validated biomarkers for emphysema is now greater than ever. Among the many biomarkers for emphysema that have been considered to date (e.g., radiographic measures, biochemical tests, patientcentered instrument-based assessments, etc.), desmosine and isodesmosine have held longstanding appeal because of a compelling model by which they should refl ect emphysema progression. As pointed out by Ma et al. (1) in the accompanying article, desmosine and isodesmosine (DI) occur as amino acid cross-links only in mature elastin, a major (though not exclusive) source of which is the lung. Th e underlying model has been that, as emphysema progresses, elastin is degraded, and its degradation products, DI, will appear in increased amounts in various fl uids such as plasma, urine, and bronchoalveolar fl uid (BALF). Interest in DI as a biomarker in AATD has been steady, with multiple available studies spanning almost two decades (2–5). As appealing as the elastin degradation product (EDP) concept has been for emphysema in general and for AATD in particular, results regarding whether EDPs decrease with augmentation therapy in AATD have been largely disappointing to date (3, 4). Specifi cally, the few available studies assessing the impact of alpha-1 antitrypsin augmentation therapy on EDPs have largely shown no signifi cant changes in DI levels before vs. after administering augmentation therapy, thereby challenging their value as biomarkers of emphysema progression. Understandably, this experience had somewhat dampened enthusiasm about DI as a biomarker in AATD – at least until now. Th e current study by Ma et al. (1) lends a spark of enthusiasm for the role of DI as a biomarker for assessing treatment of AATD. In a study of diverse patients who received diff erent augmentation therapy interventions (i.e., intravenous augmentation in conventional doses and recombinant inhaled augmentation therapy) and from whom diff erent specimens were collected (i.e., plasma, urine, and BALF), their fi ndings restore an appetite for value of DI as a biomarker in emphysema. Briefl y, the key fi ndings of the current study were:

Autocorrelation properties of temporal networks governed by dynamic node variables

Two types of densification scaling in the evolution of temporal networks

Temporal networks with node-specific memory: unbiased inference of transition probabilities, relaxation times and structural breaks

Correlation and Autocorrelation of Data on Complex Networks

-temporal random hyperbolic graphs

Modeling Temporal Networks with Bursty Activity Patterns of Nodes and Links.

Elastin Degradation Products as Biomarkers in Alpha-1 Antitrypsin Deficiency: Lastin’ Impact?

$(ω_1, ω_2)$-temporal random hyperbolic graphs

The Fundamental Advantages of Temporal Networks.

Dynamic Chain Graph Models for Ordinal Time Series Data

Autoregressive Networks with Dependent Edges

Temporally Factorized Network Modeling for Evolutionary Network Analysis.

Temporal local clustering coefficient uncovers the hidden pattern in temporal networks

Modelling sparsity, heterogeneity, reciprocity and community structure in temporal interaction data

Higher-order correlations reveal complex memory in temporal hypergraphs

Detecting periodic time scales of changes in temporal networks

Graph Metrics for Temporal Networks

Temporal Link Prediction Using Graph Embedding Dynamics

A Perturbative Solution to the Linear Influence/Network Autocorrelation Model Under Network Dynamics

Detecting periodic time scales in temporal networks

Cross-linked structure of network evolution